Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer

Enzalutamide (MDV3100) is a second generation Androgen Receptor (AR) antagonist with proven efficacy in the treatment of castration resistant prostate cancer (CRPC). The majority of treated patients, however, develop resistance and disease progression and there is a critical need to identify novel t...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Kregel, Steven, Chen, James L., Tom, Westin, Krishnan, Venkatesh, Kach, Jacob, Brechka, Hannah, Fessenden, Tim B., Isikbay, Masis, Paner, Gladell P., Szmulewitz, Russell Z., Vander Griend, Donald J.
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2016
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5041979/
https://ncbi.nlm.nih.gov/pubmed/27036029
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8456
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky